Skip to main content

Table 2 Comparison of liver function tests at week 4 after initiation of antituberculosis drugs

From: A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury

  Silymarin Placebo p-value
(N = 27) (N = 28)
ALT (IU/L) 32 (20, 184) 35 (15, 415) 0.455
AST (IU/L) 26 (14, 219) 29 (13, 386) 0.888
ALP (IU/L) 78 (37, 409) 85 (56, 249) 0.622
GGT (IU/L) 61 (13, 224) 99 (21, 366) 0.215
TP (g/L) 74.2 (25.1, 90.8) 73.3 (48.7, 93.7) 0.920
Alb (g/L) 33.6 (8, 41) 35.0 (19, 69) 0.565
TB (mg/dl) 0.6 (0.2, 2.2) 0.6 (0.2, 6.5) 0.999
DB (mg/dl) 0.3 (0.1, 1.4) 0.3 (0.1, 5.0) 0.999
  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TP, total protein; Alb, albumin; TB, total bilirubin; DB, direct bilirubin
  2. Continuous variables reported as median (interquartile range)